Actuate Therapeutics Inc (ACTU)
NASDAQ: ACTU
· Real-Time Price · USD
8.00
-0.22 (-2.68%)
At close: Aug 15, 2025, 3:59 PM
8.12
1.56%
After-hours: Aug 15, 2025, 04:10 PM EDT
-2.68% (1D)
| Bid | 7.34 |
| Market Cap | 163.66M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -25.31M |
| EPS (ttm) | -3.15 |
| PE Ratio (ttm) | -2.54 |
| Forward PE | -6.02 |
| Analyst | Buy |
| Ask | 8.49 |
| Volume | 40,076 |
| Avg. Volume (20D) | 109,427 |
| Open | 8.16 |
| Previous Close | 8.22 |
| Day's Range | 7.76 - 8.22 |
| 52-Week Range | 5.47 - 11.99 |
| Beta | 0.08 |
About ACTU
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ACTU
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ACTU stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
+0.48%
ACTU stock has given up its prior gain. Actuate Th...
Unlock content with
Pro Subscription
1 month ago
+0.48%
Actuate Therapeutics shares are trading higher after the company announced it will initiate the planning of its Phase 2 trial of Elraglusib.